Cantor Fitzgerald Begins Coverage on AgomAb Therapeutics (NASDAQ:AGMB)

Equities research analysts at Cantor Fitzgerald began coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage set an “overweight” rating on the stock.

A number of other research firms have also commented on AGMB. Wall Street Zen lowered shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. HC Wainwright initiated coverage on shares of AgomAb Therapeutics in a research note on Monday, June 22nd. They set a “buy” rating and a $35.00 target price for the company. Finally, B. Riley Financial started coverage on shares of AgomAb Therapeutics in a report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 target price on the stock. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.00.

AgomAb Therapeutics Trading Up 0.4%

AgomAb Therapeutics stock opened at $13.73 on Wednesday. The business has a 50 day moving average of $12.67. AgomAb Therapeutics has a one year low of $8.75 and a one year high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last released its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. Equities analysts predict that AgomAb Therapeutics will post -1.77 earnings per share for the current fiscal year.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.